Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 19/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 5/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 3/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 2/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.56 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7178273 | 0.99 | ITGAV (0.98) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL7178288 | 0.99 | ITGAV (0.98) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL6668814 | 0.97 | ITGAV (0.94) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL7174929 | 0.96 | ITGAV (0.93) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL7174900 | 0.96 | ITGAV (0.93) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL6667521 | 0.95 | ITGAV (0.90) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL6667621 | 0.94 | ITGAV (0.90) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL6672477 | 0.94 | ITGAV (0.90) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL6668694 | 0.94 | ITGAV (0.90) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL7171956 | 0.94 | ITGAV (0.88) | ITGAVITGB3ITGA2BITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153014-B1 | BETA-ALANINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-09-22 | — | — | EP | claimed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8404862-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404862-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8017763-B2 | Chemically modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090280118-A1 | antibody that binds the same epitope of alpha v beta 5 as bound by ALULA ; Pulmonary edema | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280118-A1 | antibody that binds the same epitope of alpha v beta 5 as bound by ALULA ; Pulmonary edema | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-11-12 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1153014-B1 | BETA-ALANINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-09-22 | — | — | EP | disclosed |
| US-20040157902-A1 | Integrin antagonists | MERCK PATENT GMBH (DE) | 2004-08-12 | — | — | US | disclosed |
| US-6576637-B1 | Such as 3-(4-methyl-3-nitrophenyl)-3-(2-(4-(pyridin-2-yl-amino)butyryl amino)acetylamino)propionic acid; thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, | MERCK PATENT GMBH (DE) | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280118-A1 | antibody that binds the same epitope of alpha v beta 5 as bound by ALULA ; Pulmonary edema | ITGA5, ITGAV, ITGB5 | ITGAV 2/4885ITGB3 12/4885ITGA2B 13/4885 |
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | ITGAV 799/4885ITGB3 1717/4885ITGA2B 1423/4885 |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | NSUN2, RNGTT, DCLRE1B | ITGAV 955/4885ITGB3 829/4885ITGA2B 903/4885 |
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | ITGAV 384/4885ITGB3 174/4885ITGA2B 219/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | ITGAV 799/4885ITGB3 1717/4885ITGA2B 1423/4885 |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | ITGAV 384/4885ITGB3 174/4885ITGA2B 219/4885 |
| US-20040157902-A1 | Integrin antagonists | ITGB1, ITGA1, ITGB2 | ITGAV 8/4885ITGB3 5/4885ITGA2B 10/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | ITGAV 384/4885ITGB3 174/4885ITGA2B 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.